Skip to main content

Table 6 Lipid parameters with dapagliflozin in increased LDL-C and decreased LDL-C subgroup

From: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

 

Increased LDL-C group (n = 20)

Decreased LDL-C group (n = 20)

p valuesb

p valuesc

Pre treatment

Post treatment

% change

p valuesa

Pre treatment

Post treatment

% change

p valuesa

Total-C (mg/dL)

188.9 ± 31.3

211.4 ± 43.1

11.9

<0.001*

198.4 ± 41.8

184.8 ± 45.8

−6.9

0.002*

0.428

<0.0001*

TG (mg/dL)

161.3 ± 69.5

151.6 ± 89.4

−6.0

0.440

123.0 ± 51.8

114.8 ± 54.6

−6.7

0.360

0.029*

0.920

HDL-C (mg/dL)

45.4 ± 8.5

52.0 ± 9.7

14.5

0.001*

51.5 ± 12.7

55.1 ± 16.0

7.0

0.070

0.082

0.242

LDL-C (mg/dL)

116.8 ± 23.0

133.4 ± 33.1

14.2

0.002*

119.8 ± 40.1

103.5 ± 41.0

−13.6

<0.001*

0.771

<0.0001*

Apo AI (mg/dL)

126.1 ± 17.8

140.4 ± 18.4

11.3

<0.001*

141.4 ± 22.9

146.8 ± 26.4

3.8

0.230

0.025*

0.145

Apo AII (mg/dL)

29.5 ± 4.8

32.3 ± 5.1

9.5

<0.001*

29.9 ± 4.3

29.5 ± 4.6

−1.3

0.530

0.798

0.001*

Apo B (mg/dL)

100.9 ± 17.6

111.8 ± 22.3

10.8

<0.001*

99.3 ± 30.0

85.0 ± 34.7

−14.4

0.014*

0.846

<0.0001*

Apo CII (mg/dL)

4.8 ± 1.8

5.4 ± 2.5

12.5

0.057

4.7 ± 1.6

4.5 ± 1.8

−4.3

0.270

0.855

0.029*

Apo CIII (mg/dL)

10.7 ± 3.6

12.0 ± 4.8

12.1

0.035*

10.2 ± 2.8

10.7 ± 3.8

4.9

0.340

0.698

0.240

Apo E (mg/dL)

4.3 ± 1.1

4.6 ± 1.7

7.0

0.280

4.4 ± 1.2

4.3 ± 1.3

−2.3

0.420

0.904

0.193

RLP-C (mg/dL)

7.6 ± 5.0

7.8 ± 2.5

2.6

0.870

5.7 ± 3.3

5.0 ± 3.3

−12.3

0.090

0.136

0.809

HDL2-C (mg/dL)

23.5 ± 5.1

29.1 ± 7.8

23.8

<0.001*

28.8 ± 10.03

32.5 ± 13.3

12.8

0.080

0.043*

0.437

HDL3-C (mg/dL)

21.8 ± 4.0

22.8 ± 4.9

4.6

0.410

22.6 ± 3.6

22.5 ± 5.2

−0.4

0.890

0.476

0.450

sd LDL-C (mg/dL)

62.0 ± 25.5

49.5 ± 24.5

−20.2

0.048*

46.3 ± 21.4

37.3 ± 23.2

−19.4

0.015*

0.046*

0.655

lb LDL-C (mg/dL)

54.7 ± 25.3

83.5 ± 32.3

52.7

<0.001*

73.4 ± 27.3

66.1 ± 34.4

−9.9

0.010*

0.033*

<0.0001*

sd LDL-C/LDL-C

0.53 ± 0.18

0.37 ± 0.17

−30.2

0.003*

0.38 ± 0.00

0.35 ± 0.17

−7.9

0.250

0.005*

0.021*

  1. Data are expressed as mean ± standard deviation or percent changes after the treatment. Clinical and laboratory parameters in the subgroup whose LDL-C was increased or decreased by dapagliflozin treatment were analyzed
  2. Total-C total-cholesterol, TG triglycerides, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, Apo apolipoprotein, RLP-C remant-like particles-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol
  3. ap values for the intragroup comparison (pre vs. post treatment values in each subgroup, * p < 0.05)
  4. bp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the pre treatment values, * p < 0.05)
  5. cp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the changes from pre to post treatment, * p < 0.05)
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840